joining you thank for and us. afternoon Good all Johnny. you, Thank
$XX.X increase Joining XX% in We're Financial first XXXX. is revenues quarter our me off to million CFO, of the on highlights call solid an start today of a our year-over-year. Mendel. from Scott include
flu an respiratory exceptionally high Our performance by was testing season. strong volumes driven in
quarter the contributed ePlex in revenues time revenue our XT-X and our system surpassed meaningfully to addition, from contribution In for system. first again the
pleased labs of of we're the ePlex panel U.S. expectations by initial driven respiratory was exceeding see our across many the strong this shift largest adoption revenues our anticipated, pathogen to While by
season expanded placements IVD quarter and most largest placements. were on able The platform four of commercial the we were to QX driven high three the volumes U.S. testing past labs yes, ePlex ePlex months, respiratory and to strides managing flu focused ePlex by teams testing European closed XXX majority were with the with In During and quarter severe our our extremely in XX installed strong the the the in of make still and our labs. analyzers market first our base panels. placements for by U.S.,
our instrumental over us demand. exceptionally cartridges. to keep in That manufacturing last gross highlights, automation initiatives focus by the demand margins with customer our for manufacturing RP to high customer fulfill lower Turning primary ePlex The in test were the we demand said, business was internal were additional yield to year, up we implemented quarter impacted as to prioritized enabling and in our yield. improve quarter the line a
the margin flu off in we future weeks, see expansion and As designed manufacturing increase in quarters. implementing to expect yield begun improvements, recent process we have season gross to tapered has
manufacturing line ePlex help menu flu In ongoing and addition, season to our third plans for the our we service accelerating a are XXXX-'XX expansion.
pathogens U.S., we Customer FDA in positive are ID implementation which up, held our Disease are revenue blood and by clearance, were our we decentralized processing for competitors displace and especially Microbiology We sales now momentum There, accelerating and strategic in other published later to to recently as literature repositioned and build Europe, or this, benefits Clinical to impact reflected may we market we are of in one contribute across on flu in patient analysis improved management, highlighted some In expansion sites And to the positive to accounts to grow during key now And also installed savings meaningful their placement the in to ePlex these flu the In testing Scotland base improve lower Europe Spain. impact Infectious reduction last to of system. we expect utilization shared cost to experience highlighted pick analyzers impact additional on season testing XXXX, expand begun momentum capacity sites of isolation to ePlex our we and receive to or that Congress call, from we a to RP can on leave our use force with we’ve sales these U.S. that have in U.S. distributor Florida. most in mid-XXs. hospital ePlex season, RP initiatives generation. multiplex rapid largest in Symposium look at of Overall patient week for leading approach multiple was Virology these and with this the order encouraged the Europe. next and ease partnerships performance, as other NP strong QX to Based ePlex that our force in to potential to and to the patient XXXX continuing testing at the of market annuity under-utilized culture are European for year reported RP to our we opportunities routine CVS reporting markets, subsided, to address in admissions XXXX this the panels initiatives the at health translated concluded forward Europe saw evaluate season suggested new be ePlex flu preliminary and placement the of as of key well we in steady be volume and sites and our this hospitals cycle European feedback ’XX from Meeting on on lower expect continue data during anticipated was our net identify positive year customer the bed the historically making the plan the of progress as from the have results. processes meaningful on respiratory acquisition utilization. with and the the benefits ECCMID, shorten season. commercial in on ePlex, respiratory this and Clinical launched room a This we anti-microbial experience sites. inform recently Consistent molecular the of the into ePlex
progress Turning towards making culture three market. IV to to unique ePlex very expansion, the we good menu panels delivering blood U.S. are
of culture of We forward driving external family are tests IV U.S. support studies of our submission. blood in internal and FDA
positive finalizing yet not completed study elaborate ready the are results, with and while sites or Gram we’re and testing specific All clinical been by pleased on to to-date. We clinical are close has we’re submission sample we progress preparing to shortly. for the details clinical BCID very
continue these fungal We’re negative studies submission also FDA preparing and to BCID to to expect of and clinical this gram the year. panels commence the
As in over expansions. growing QX focused we many utilizing the number testing prioritize I customers for internal mentioned earlier clinical our their we routine and on initiatives high of were ePlex RP panel extremely including for supporting demand
to fungal for of the now the we panels in third gram FDA result negative and this As second quarters on the panel expect a the quarter of and the in fourth submit XXXX. review submission expect gram slight of and a remain track year positive subject the year clearance in panel BCID delay is FDA be from the of end but by previous of will likely timing early two fungal FDA panels this we expectations. clearance to Therefore that it we
in addition to to potential and who the positive of the decision forward their are looking customers feedback anticipating We to them our menu already process. from receive BCID panels continue are
to ePlex experience at and the to evidence in week dataset to site of ECCMID sensitivity We with mul-detox Ireland demonstrated Europe. superiority to ePlex from reported BCID technology. real pilot leading deliver sensitive clinical the compared bottle reported continue the Meeting positivity also BCID performance of last direct on ePlex their world in produce BCID highly compared improved Spain. data panels for BCID mul-de. on adopters results early This in Three One utility the
XXX% and rapid ePlex the results panel on This positive deliver, multiple poly panels from immune-compromised detect. comparing large identified versus panels fungal ePlex detection study and approximately to but sooner results blood excellent positive BCID fungal evaluated ePlex cultures. panels panels. three difficult organisms including specifically for positive, markets species to that performance blood can BCID designed can approximately perspective ePlex Notably the designed major of the mul-de were panel rework of the all to Another provide markers gram BCID a finally and relatively the acute study were the and negative broadest the day showed research number co-infection for a ePlex patients. gram candida analytical identify French And that microbial ePlex any to and many to the an molecular performance site that resistance be impact with actionable rare multiple in demonstrated samples. fungal ability that demonstrated performance X% particularly be on-panel BCID BCID culture across that can of positive, These mul-de rate delivery fungal in panels and panel one this a performed Belgium sensitivity negative site benefit gram in including for across in site gram of mul-de unique study market, inclusivity others
in demonstrating highly this targets intestinal are of panel. sample ePlex’s its look And type providing differentiated panels Scott with Given Launching on BICD priority. also infections. now the submissions with a the behind highly a multiplexed is BCID our with I position differentiated gastro the necessary resources flu his our to financial of U.S. and and finally in unique Scott? panels And controls, to bloodstream as demonstrating with clinical panel call to over we and the company critical And the XX on nature over will other progress ePlex of now ePlex turn forward future. we're season these pathogen studies GI updates possible. in reportable the for us FDA review. complete diagnosis diseases state further I challenging is that significant and as and utility menu ePlex most soon making important very dedicating the
